The study on effectively treating liver fibrosis in the CCL4‐induced liver cirrhosis model by using bone marrow mesenchymal stem cells (MSCs) that overexpressed the Smad7 gene demonstrated that inhibition of TGF‐β1 signaling pathway by enhancement of Smad‐7 expression could be a feasible cell therapy approach to mitigate liver cirrhosis,151 which is also worth testing in LTS as a potential therapy. The gene discussed is TGFB1; the disease is cirrhosis of liver.